Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.
In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.
Here, we will give a short insight into our published results: Original publications
| Eingeschlossene Patienten: 23.234 (Stand 02. Januar 2025) | |
|---|---|
| Amgevita® (Adalimumab) | 240 |
| Benepali® (Etanercept) | 1244 |
| Cimzia® (Certolizumab) | 1041 |
| Enbrel® (Etanercept) | 2876 |
| Erelzi® (Etanercept) | 576 |
| Flixabi® (Infliximab) | 10 |
| Hukyndra® (Adalimumab) | 10 |
| Hulio® (Adalimumab) | 266 |
| Humira® (Adalimumab) | 2910 |
| Hyrimoz® (Adalimumab) | 247 |
| Idacio® (Adalimumab) | 68 |
| Imraldi® (Adalimumab) | 238 |
| Inflectra™ (Infliximab) | 16 |
| Jyseleca® (Filgotinib) | 159 |
| Kevzara® (Sarilumab) | 223 |
| Kineret® (Anakinra) | 89 |
| MabThera® (Rituximab) | 1459 |
| Nepexto® (Etanercept) | 94 |
| Olumiant® (Baricitinib) | 547 |
| Orencia® (Abatacept) | 992 |
| Remicade® (Infliximab) | 762 |
| Remsima® (Infliximab) | 26 |
| Rinvoq® (Upadacitinib) | 315 |
| Rixathon® (Rituximab) | 20 |
| RoActemra® (Tocilizumab) | 1378 |
| Ruxience® (Rituximab) | 1 |
| Simponi® (Golimumab) | 476 |
| Truxima® (Rituximab) | 3 |
| Tyenne® (Tocilizumab) | 41 |
| Xeljanz® (Tofacitinib) | 398 |
| Yuflyma® (Adalimumab) | 48 |
| Zessly® (Infliximab) | 2 |
| Kontrollen | 6459 |
